USF TrialNet Clinical Center

$411,342U01FY2014DKNIH

University Of South Florida, Tampa FL

Investigators

Linked publications & trials

Paper 39670998 Paper 39167668 Paper 39103721 Paper 38712386 Paper 38621411 Paper 37940642 Paper 37000695 Paper 36920087 Paper 36326757 Paper 36175392 Paper 35998266 Paper 35880956 Paper 35524749 Paper 35041021 Paper 34853027 Paper 34850014 Paper 34747368 Paper 34642772 Paper 34620616 Paper 34551936 Paper 33658358 Paper 33496819 Paper 33441381 Paper 33424774 Paper 33277338 Paper 32844178 Paper 32833543 Paper 32669415 Paper 32573495 Paper 32502242 Paper 32457058 Paper 32404353 Paper 32019856 Paper 32003110 Paper 31982961 Paper 31937610 Paper 31867614 Paper 31794865 Paper 31768570 Paper 31558546 Paper 31180194 Paper 31167877 Paper 30967424 Paper 30894366 Paper 30891858 Paper 30830871 Paper 30830868 Paper 30730939 Paper 30709843 Paper 30629603 Paper 30552130 Paper 30405601 Paper 30275285 Paper 30232284 Paper 30167735 Paper 30089716 Paper 30061316 Paper 30012675 Paper 29931415 Paper 29925930 Paper 29851415 Paper 29769238 Paper 29429978 Paper 29171129 Paper 29164254 Paper 29040630 Paper 29025879 Paper 28956083 Paper 28860125 Paper 28821222 Paper 28770323 Paper 28707353 Paper 28531305 Paper 28520980 Paper 28500393 Paper 28226181 Paper 28202550 Paper 28177779 Paper 27704166 Paper 27579340 Paper 27456836 Paper 27422577 Paper 27385327 Paper 27362539 Paper 27208341 Paper 27114212 Paper 26995649 Paper 26991448 Paper 26822082 Paper 26676824 Paper 26642366 Paper 26578518 Paper 26375197 Paper 26336066 Paper 26068542 Paper 25773405 Paper 25758770 Paper 25720600 Paper 25524915 Paper 25039804

Abstract

DESCRIPTION (provided by applicant): The objectives of Type 1 Diabetes TrialNet are to delay or prevent the development of T1D in persons at risk and to preserve ¿-cell function in those with T1D possessing residual ¿-cell function through a highly collaborative network designed to identify individuals at-risk for T1D and to determine their eligibility for- and enrollment into prevention trials and to perform new- onset intervention trials. The USF Diabetes Center has been a very productive Affiliate of the University of Florida and has engaged with the TrialNet Coordinating Center at the University of South Florida to develop novel approaches to increase TrialNet enrollment. The Center is comprised of a committed multi-disciplinary team operating from a state-of-the-art, dedicated clinical and clinical research facility serving greater than 1,400 pediatric and adult patients with T1D. In addition, it has established a regional collaborative network of diabetes care providers with access to thousands of additional existing- and new-onset T1D patients. The PI's experience, including roles as the Indiana University DPT-1 Regional Recruitment Center Director, former Director of the Indiana University TrialNet Clinical Center, and as Chair of the Pathway to Prevention Study, and his successful engagement of T1D stakeholders, have enabled him to make vital contributions to TrialNet and has provided him with valuable insight into TrialNet's current limitations and opportunities for expansion. Funding of the USF TrialNet Clinical Center will greatly enhance his involvement in TrialNet as a voting member of the Steering Committee, potential member of the Clinical Leadership Committee, and collaborator of the Clinical Network Hub. Funding will also permit marked expansion of TrialNet recruitment in the West Central Florida region and gain access to hereto for untapped at-risk populations. The USF Diabetes Center's commitment to pursue clinical studies seeking to ameliorate the development of T1D is evidenced by the marked increase in our TrialNet screening activity, the number of our diabetes clinical trails, and our work with the TrialNet TNCC to develop innovative screening initiatives. Our participation as a TrialNet Clinical Center will permit us to markedly expand our current collaborative efforts on behalf of TrialNet.

View original record on NIH RePORTER →